Patents Assigned to Eyegate Pharma, S.A.
-
Patent number: 9238131Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to received a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.Type: GrantFiled: May 21, 2013Date of Patent: January 19, 2016Assignee: EYEGATE PHARMA S.A.S.Inventor: Pierre Roy
-
Patent number: 9192512Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.Type: GrantFiled: May 23, 2014Date of Patent: November 24, 2015Assignee: EYEGATE PHARMA S.A.S.Inventors: Francine Behar-Cohen, Pierre Roy
-
Patent number: 8771256Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.Type: GrantFiled: October 27, 2010Date of Patent: July 8, 2014Assignee: Eyegate Pharma S.A.Inventors: Francine Behar-Cohen, Pierre Roy
-
Patent number: 8611994Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.Type: GrantFiled: March 8, 2011Date of Patent: December 17, 2013Assignee: EyeGate Pharma S.A.S.Inventor: Pierre Roy
-
Patent number: 8452391Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to received a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.Type: GrantFiled: December 15, 2011Date of Patent: May 28, 2013Assignee: EyeGate Pharma S.A.S.Inventor: Pierre Roy
-
Patent number: 8306613Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.Type: GrantFiled: August 25, 2011Date of Patent: November 6, 2012Assignee: EyeGate Pharma S.A.S.Inventor: Pierre Roy
-
Publication number: 20120089077Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to received a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.Type: ApplicationFiled: December 15, 2011Publication date: April 12, 2012Applicant: EYEGATE PHARMA, S.A.S.Inventor: Pierre ROY
-
Patent number: 8099162Abstract: The invention relates to a device of ocular iontophoresis for delivering active substances, comprising a reservoir having an outer wall and a hollow body at least partly delimited by the outer wall, wherein the hollow body is capable of receiving an electrical conductive medium and active substances contained in the medium and has an outlet defining a surface, so-called “application surface”, intended to receive a determine part of an eyeball surface, the application surface being at least partly limited by an outer line concave towards the optical axis of the eyeball, wherein the outer wall extends from the outer line with a global outwardly with respect to the said optical axis.Type: GrantFiled: December 9, 2005Date of Patent: January 17, 2012Assignee: EyeGate Pharma, S.A.S.Inventor: Pierre Roy
-
Publication number: 20110306923Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.Type: ApplicationFiled: August 25, 2011Publication date: December 15, 2011Applicant: EYEGATE PHARMA, S.A.S.Inventor: Pierre Roy
-
Patent number: 7937142Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.Type: GrantFiled: May 8, 2009Date of Patent: May 3, 2011Assignee: EyeGate Pharma S.A.S.Inventor: Pierre Roy
-
Patent number: 7848800Abstract: The invention concerns a device for ocular application of an active principle (1) comprising a main electrode (2) including an insulating layer, an adhesive layer designed to bind the insulating layer to a conductive layer, characterized in that the main electrode comprises a zone (21, 22) designed to be urged into contact with an eyelid.Type: GrantFiled: October 11, 2002Date of Patent: December 7, 2010Assignee: Eyegate Pharma S.A.S.Inventors: Francine Behar-Cohen, Pierre Roy
-
Patent number: 7771403Abstract: The feed connector (270) capable of interacting with a device for delivering active principles comprising a reservoir delimited by at least two lateral walls of substantially cylindrical shape and extending opposite one another, is characterized in that it includes means (202, 203, 204, 205) for dispensing active principles into the reservoir that are arranged such that said reservoir is filled substantially uniformly between the two lateral walls.Type: GrantFiled: March 3, 2004Date of Patent: August 10, 2010Assignee: Eyegate Pharma S.A.Inventor: Pierre Roy
-
Patent number: 7684857Abstract: The invention concerns a device for ocular delivery of an active principle by peroperative intraocular iontophoresis or electroporation comprising a reservoir (7) for receiving a solution comprising the active principle, means for diffusing (8, 6) the active principle connected to the reservoir, means for injecting (4) the solution into the reservoir, and means (5) for exerting suction of the content of the reservoir during an injection of the solution therein by the injection means.Type: GrantFiled: October 11, 2002Date of Patent: March 23, 2010Assignee: Eyegate Pharma S.A.S.Inventors: Francine Behar, Pierre Roy
-
Patent number: 7628781Abstract: The invention relates to a connector assembly (10) for the transfer of fluids, particularly fluids comprising an active agent from a reservoir to a medical device for dosage, comprising: a first connector element (20), pertaining to the reservoir with first fixing means (23), a second connector element (10), pertaining to the medical dosage device with second fixing means (12), cooperating with the first fixing means to give an irreversible connection between the two elements. The first and second elements are embodied such as to cooperate with other by clipping on a single translational movement of a connector element relative to the other to produce the irreversible connection, characterized in that at least one of the connection elements is embodied with means to render the same breakable.Type: GrantFiled: March 7, 2003Date of Patent: December 8, 2009Assignee: Eyegate Pharma S.A.S.Inventors: Pierre Roy, Alain Kleinsinger
-
Patent number: 7548778Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.Type: GrantFiled: January 8, 2007Date of Patent: June 16, 2009Assignee: Eyegate Pharma S.A.S.Inventor: Pierre Roy
-
Patent number: 7164943Abstract: The invention provides an ocular iontophoresis device for delivering medication, the device comprising a medication reservoir suitable for being positioned on the eye, at least one medication in solution in the reservoir, an active electrode disposed in the reservoir, and a passive electrode, the device including at least one medication dissolved in non-saline water, the said solution having a pH lying in the range 6.5 to 8.5, the medication having a pKa lying in the range about 5.5 to about 9.5 and includes an active principle which is associated with an additive, such as a dendrimer, a polymer, a nanoparticle, a microsphere, a liposome, or an emulsion, and having an ionic form of valency greater than or equal to 1.Type: GrantFiled: June 3, 2004Date of Patent: January 16, 2007Assignee: Eyegate Pharma, S.A.Inventor: Pierre Roy